Your molecule
Latin America
A strategic partner
Active regional infrastructure in high-potential pharmaceutical markets
From Mexico to Central America and the Caribbean, LMG Bio connects pharmaceutical manufacturers with institutional access, coordination regulatory and specialized regional execution.
Units distributed thru from our regional network in 2025
Guatemala: IGSS = Guatemalan Social Security Institute.
Honduras: IHSS = Honduran Social Security Institute.
El Salvador: ISSS = Salvadoran Social Security Institute.
Costa Rica: CCSS = Costa Rican Social Security Fund.
Panama: CSS = Social Security Fund.
Dominican Republic: SeNaSa = National Health Insurance.
Mexico: IMSS = Mexican Social Security Institute. ISSSTE = Institute for Social Security and Services for State Workers.
Birmex = Biological and Reagent Laboratories of Mexico (a state-owned company that will consolidate its position as a central buyer and distributor by 2030).
Mexico: The world’s largest Spanish-speaking pharmaceutical market.
Entering Latin America without the correct infrastructure can cost more than the market opportunity
Regulatory Complexity
Multiple regulatory frameworks, different approval times, and local requirements make market entry to the market is complex without specialized regional experience.
Institutional Access Gap
Public institutions such as CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa require established relationships, experience in bidding and local execution capacity.
Channel Risk
Generic distribution networks often lack specialization, active sell-out management, and
focus on the institutional pharmaceutical market.
Multi-country Coordination Cost
Managing distributors, contracts, and compliance processes separately in multiple countries increases costs, risk, and operational complexity.
There is a better way to enter the region: not by building infrastructure country by country, but by teaming up with the team that already has it built
An entity in the U.S. Simplified regional access
Global pharmaceutical manufacturers work with a single strategic partner based in United States. LMG Bio coordinates the regulatory, commercial, and operational pathway in Mexico, Central America and the Caribbean.
Global Manufacturers
LMG Bio Lifesciences LLC (Miami, FL)
The interface layer. This is where manufacturers engage. We handle: international contracts under U.S. law · compliance & regulatory strategy · licensing agreements · supply chain coordination · market intelligence (IQVIA) · institutional tender strategy. You sign one contract. We manage the rest — across Mexico, Central America, and the Caribbean, with a clear roadmap to the rest of Latin America.
Lanco Medical Group · Regional Operations
The execution layer. 30+ years building the infrastructure that makes Latin America work. Operating across Mexico, Panama, Costa Rica, Guatemala, Honduras, El Salvador & Dominican Republic: RTCA regulatory filings · institutional tender management · qualified distribution network · medical sales force · key account management in public & private sector.
The Market · $80B+ Latin American Regional Opportunity
CSS (Panama) · CCSS (Costa Rica) · IGSS (Guatemala) · IHSS (Honduras) · ISSS (El Salvador) · SeNaSa (Dominican Republic). Over 144 million units consumed in the region in 2025. Public and private channels. Biosimilars, specialty molecules, generics.
Designed for the global pharmaceutical industry
Executed with regional experience
Five capabilities. One integrated partner.
Information driven by IQVIA to assess demand,
competition, prices, and therapeutic opportunities before enter the market.
Regulatory coordination RTCA and Mexico for generics, biosimilars and specialized therapies.
Direct experience with public institutions and processes bidding in Central America and the Caribbean.
Validated regional partners, with pharmaceutical specialization, institutional focus and active channel management.
An entity based in the United States designed to
simplify contracts, compliance processes, and onboarding of
pharmaceutical manufacturers.
The trust of global pharmaceutical manufacturers
Backed by regional execution
International pharmaceutical companies rely on the LMG ecosystem to navigate market access, the regulatory complexity and institutional opportunities throughout the region.
Active markets
Units distributed in 2025
Strategic entity based in the U.S.
Regional network of institutional access
Years building pharma infrastructure across Latin America
Beyond distribution
A pharmaceutical access platform for the region
Latin America offers a great opportunity for the pharmaceutical industry, but access remains fragmented among regulatory systems, institutions, and distribution networks. LMG Bio integrates all these layers thru a strategic interface based in the U.S. and a proven regional execution ecosystem.
Our partners do not just gain access to distribution. They access infrastructure.
An ecosystem
Three strategic layers
Strategic hub based in Miami, Florida. Contracts under structure American, compliance, licensing, and market access intelligence market.
Regional execution platform. RTCA, institutional tenders, distribution specialized and sales force focused on the pharmaceutical industry.
Institutional access in the U.S. for partners with expansion goals in the American market.
Find out if your molecule has market potential in Latin America
In 20 minutes, we can assess the potential of your product in Mexico, Central America and the Caribbean.
● Market potential by therapeutic area
● Presence of competitors and barriers to entry
● Overview of the regulatory pathway
● Alliance model with LMG Bio